Artelo presents favorable human metabolite profile for non-opioid pain candidate
Artelo Biosciences (NASDAQ:ARTL) announced encouraging human metabolite identification and profiling data for its lead drug candidate, ART26.12, as the biotechnology company aims to de-risk the development of its novel non-opioid pain therapy.










